143 related articles for article (PubMed ID: 30307747)
1. How to Validate Predictive Immunohistochemistry Testing in Pathology? A Practical Approach Exploiting the Heterogeneity of Programmed Death Ligand-1 Present in Non-Small Cell Lung Cancer.
Thunnissen E
Arch Pathol Lab Med; 2019 Jan; 143(1):11-12. PubMed ID: 30307747
[No Abstract] [Full Text] [Related]
2. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
Heymann JJ; Bulman WA; Swinarski D; Pagan CA; Crapanzano JP; Haghighi M; Fazlollahi L; Stoopler MB; Sonett JR; Sacher AG; Shu CA; Rizvi NA; Saqi A
Cancer Cytopathol; 2017 Dec; 125(12):896-907. PubMed ID: 29024471
[TBL] [Abstract][Full Text] [Related]
4. Utility of PD-L1 testing on non-small cell lung cancer cytology specimens: An institutional experience with interobserver variability analysis.
Kravtsov O; Hartley CP; Sheinin Y; Hunt BC; Felix JC; Giorgadze T
Ann Diagn Pathol; 2020 Oct; 48():151602. PubMed ID: 32877833
[No Abstract] [Full Text] [Related]
5. Predictive markers in lung cancer: a few hints for the practicing pathologist.
Barbareschi M; Barberis M; Buttitta F; Doglioni C; Fiorentino M; Fontanini G; Franco R; Marchetti A; Rossi G; Troncone G
Pathologica; 2018 Mar; 110(1):29-38. PubMed ID: 30259911
[TBL] [Abstract][Full Text] [Related]
6. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
[TBL] [Abstract][Full Text] [Related]
7. Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease.
Shibaki R; Murakami S; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Motoi N; Kusumoto M; Yamamoto N; Ohe Y
Med Oncol; 2019 Apr; 36(6):49. PubMed ID: 31030326
[TBL] [Abstract][Full Text] [Related]
8. Quantification of PD-L1 and PD-1 expression on tumor and immune cells in non-small cell lung cancer (NSCLC) using non-enzymatic tissue dissociation and flow cytometry.
Chargin A; Morgan R; Sundram U; Shults K; Tsay EL; Ratti N; Patterson BK
Cancer Immunol Immunother; 2016 Nov; 65(11):1317-1323. PubMed ID: 27565980
[TBL] [Abstract][Full Text] [Related]
9. The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
Takada K; Okamoto T; Toyokawa G; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
Lung Cancer; 2017 Feb; 104():7-15. PubMed ID: 28213003
[TBL] [Abstract][Full Text] [Related]
10. Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy.
Mansfield AS; Dong H
Clin Pharmacol Ther; 2016 Sep; 100(3):220-2. PubMed ID: 26916808
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma.
Parra ER; Villalobos P; Mino B; Rodriguez-Canales J
Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):83-93. PubMed ID: 28719380
[TBL] [Abstract][Full Text] [Related]
12. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
[TBL] [Abstract][Full Text] [Related]
13. The Use of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Cytology Specimens for Programmed Death Ligand 1 Immunohistochemistry Testing in Non-Small Cell Lung Cancer.
Stoy S; Rosen L; Murgu S
J Bronchology Interv Pulmonol; 2017 Jul; 24(3):181-183. PubMed ID: 28696962
[No Abstract] [Full Text] [Related]
14. Optimal Evaluation of Programmed Death Ligand-1 on Tumor Cells Versus Immune Cells Requires Different Detection Methods.
Schats KA; Van Vré EA; Boeckx C; De Bie M; Schrijvers DM; Neyns B; De Meester I; Kockx MM
Arch Pathol Lab Med; 2018 Aug; 142(8):982-991. PubMed ID: 29607663
[TBL] [Abstract][Full Text] [Related]
15. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT
Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153
[TBL] [Abstract][Full Text] [Related]
16. Assessment of Programmed Death-Ligand 1 (PD-L1) Immunohistochemical Expression on Cytology Specimens in Non-Small Cell Lung Carcinoma.
Hernandez A; Brandler TC; Zhou F; Moreira AL; Schatz-Siemers N; Simsir A
Am J Clin Pathol; 2019 Mar; 151(4):403-415. PubMed ID: 30534975
[TBL] [Abstract][Full Text] [Related]
17. Prominent Nucleoli and Non-glandular Feature Are Independent Predictors of PD-L1 Expression in Lung Adenocarcinoma.
Yoon N; Kim J; Maeng LS; Ahn JH; Park ES
Anticancer Res; 2018 Oct; 38(10):6003-6008. PubMed ID: 30275232
[TBL] [Abstract][Full Text] [Related]
18. The Reproducibility of the Immunohistochemical PD-L1 Testing in Non-Small-Cell Lung Cancer: A Multicentric Italian Experience.
Vigliar E; Malapelle U; Bono F; Fusco N; Cortinovis D; Valtorta E; Spyridon A; Bimbatti M; Zocchi M; Piva C; Gaudioso G; Iaccarino A; Morbini P; Pagni F
Biomed Res Int; 2019; 2019():6832909. PubMed ID: 31111063
[TBL] [Abstract][Full Text] [Related]
19. Programmed death-ligand 1 immunohistochemistry testing for non-small cell lung cancer in practice.
Mino-Kenudson M
Cancer Cytopathol; 2017 Jul; 125(7):521-528. PubMed ID: 28472551
[No Abstract] [Full Text] [Related]
20. Association Between Clinicopathological Features and Programmed Death Ligand 1 Expression in Non-small Cell Lung Cancer.
Kato Y; Kashima J; Watanabe K; Yomota M; Zenke Y; Okuma Y; Hosomi Y; Gemma A; Seike M; Okamura T
Anticancer Res; 2018 Feb; 38(2):1077-1083. PubMed ID: 29374744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
